GeneQuantum Biosciences

GeneQuantum Biosciences is a clinical-stage biopharmaceutical company dedicated to the development of innovative bioconjugate therapeutics, with a primary focus on next-generation antibody-drug conjugates (ADCs). The company leverages its proprietary iGDC (intelligent Gene-engineered Drug Conjugate) platform, which utilizes enzymatic site-specific conjugation to create highly stable and homogeneous drug candidates. This technology is designed to improve the therapeutic index and simplify the manufacturing process compared to traditional ADC methods. GeneQuantum's pipeline includes several promising candidates targeting HER2, TROP2, and Claudin 18.2 for various oncology indications. By integrating advanced linker-payload technologies with precision conjugation, the company aims to provide more effective and safer treatment options for cancer patients globally.